Pfizer (NYSE:PFE) Price Target Cut to $28.00 by Analysts at JPMorgan Chase & Co.

Pfizer (NYSE:PFE) had its target price reduced by investment analysts at JPMorgan Chase & Co. from $30.00 to $28.00 in a report issued on Wednesday,Benzinga reports. The firm presently has a “neutral” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s price objective points to a potential upside of 15.34% from the company’s previous close.

A number of other equities analysts have also recently commented on the stock. Royal Bank Of Canada raised shares of Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price target for the company in a research note on Tuesday, June 9th. Citigroup upped their target price on shares of Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 29th. Weiss Ratings upgraded Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, May 6th. UBS Group reaffirmed a “neutral” rating and set a $27.00 price target on shares of Pfizer in a research note on Wednesday, May 27th. Finally, Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a report on Saturday. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, Pfizer presently has an average rating of “Hold” and a consensus target price of $28.56.

Pfizer Price Performance

Shares of NYSE:PFE traded up $0.21 on Wednesday, hitting $24.28. The company’s stock had a trading volume of 9,945,070 shares, compared to its average volume of 42,591,492. The company has a market capitalization of $138.36 billion, a PE ratio of 18.50 and a beta of 0.35. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94. The company has a 50-day simple moving average of $25.51 and a 200 day simple moving average of $26.21. Pfizer has a 1 year low of $23.11 and a 1 year high of $28.75.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, topping the consensus estimate of $0.72 by $0.03. The company had revenue of $14.45 billion during the quarter, compared to analyst estimates of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.Pfizer’s revenue was up 5.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Sell-side analysts forecast that Pfizer will post 2.98 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Kepler Cheuvreux Suisse SA bought a new stake in shares of Pfizer during the 3rd quarter valued at $16,613,000. Mackenzie Financial Corp increased its stake in shares of Pfizer by 119.6% in the 3rd quarter. Mackenzie Financial Corp now owns 3,106,644 shares of the biopharmaceutical company’s stock worth $79,157,000 after acquiring an additional 1,691,773 shares in the last quarter. Penn Davis Mcfarland Inc. increased its stake in shares of Pfizer by 50.9% in the 4th quarter. Penn Davis Mcfarland Inc. now owns 171,332 shares of the biopharmaceutical company’s stock worth $4,266,000 after acquiring an additional 57,777 shares in the last quarter. Ameriprise Financial Inc. lifted its position in Pfizer by 48.2% during the 3rd quarter. Ameriprise Financial Inc. now owns 18,373,140 shares of the biopharmaceutical company’s stock valued at $468,174,000 after acquiring an additional 5,978,927 shares during the period. Finally, Danske Bank A S bought a new stake in Pfizer during the third quarter worth about $81,298,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer won FDA approval for IBRANCE in HER2-positive breast cancer, giving the company a new clinical and commercial milestone that could support future sales. Pfizer (PFE) Wins FDA Approval For IBRANCE In HER2 Positive Breast Cancer
• Positive Sentiment: Multiple articles highlighted Pfizer as a “dirt cheap” healthcare stock, suggesting value investors are noticing its low valuation and cash-generating profile. 2 Dirt Cheap Healthcare Stocks to Buy in July
• Positive Sentiment: Pfizer’s unusually high dividend yield is drawing attention from income investors, which can help support demand for the shares. 2 Healthcare Stocks to Buy for Their Dividends—and Why Pfizer Isn’t One of Them

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.